Fate Therapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDFate Therapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 97), indicating clear outperformance against the broad market. Earnings growth of 19% provides fundamental context to the price action. However, price is extended 42% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $2.25 | +33.98% | ABOVE |
| 50 SMA | $2.12 | +42.43% | ABOVE |
| 100 SMA | $1.70 | +77.17% | ABOVE |
| 150 SMA | $1.50 | +101.19% | ABOVE |
| 200 SMA | $1.43 | +110.51% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is FATE in an uptrend right now?
FATE has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, FATE is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is FATE overbought or oversold?
FATE's RSI (14) is 68. The stock is in neutral territory, neither overbought nor oversold.
Is FATE outperforming the market?
FATE has a Relative Strength (RS) Rating of 97 out of 99. Yes, FATE is a market leader, outperforming 97% of all stocks over the past 12 months.
Where is FATE in its 52-week range?
FATE is trading at $3.02, which is 94% of its 52-week high ($3.21) and 92% above its 52-week low ($0.91).
How volatile is FATE?
FATE has a Beta of 1.94 and 52-week volatility of 98%. It's more volatile than the S&P 500 - expect bigger swings.